Panbela Therapeutics, Inc. announced that an abstract about SBP-101 and CPP-1X (also known as DFMO or Eflornithine) research in multiple myeloma (cell lines), has been accepted for an online publication on the American Society of Hematology (ASH) meeting site in the November supplemental issue of the journal Blood. The work reflects the company's on-going collaboration with researchers from The University of Texas MD Anderson Cancer Center and will become part of the permanent ASH and Blood abstracts archive.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.36 USD | -10.00% |
|
-6.49% | -98.03% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-98.03% | 1.94M | |
+16.41% | 45.51B | |
-9.83% | 38.52B | |
+38.08% | 38.13B | |
+28.02% | 30.74B | |
-8.64% | 26.03B | |
+11.69% | 25.92B | |
+45.14% | 14.13B | |
+33.64% | 12.73B | |
-7.79% | 11.29B |
- Stock Market
- Equities
- SNBP Stock
- News Panbela Therapeutics, Inc.
- Panbela Therapeutics, Inc. Announces Acceptance of Polyamine Inhibitor Car-T Combination Abstract for Online Publication